3,4-Diaminopyridine

Independent reference data for 3,4-Diaminopyridine (CAS 54-96-6), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Amifampridine is indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients. Nevertheless, at the current time only the Firdapse brand of amifampridine is indicated for the treatment of LEMS in both adult and pediatric patients, while the Ruzurgi brand of amifampridine is indicated for the treatment of LEMS only in patients aged 6 to less than 17 years.Amifampridine is an orally available potassium channel blocker that increases acetylcholine in synaptic clefts of peripheral nerve endings and is used to treat the Lambert-Eaton myasthenic syndrome. Amifampridine is associated with a low rate of transient serum enzyme elevations during therapy but has not been linked with instances of clinically apparent acute liver injury.

Synonyms and trade names

3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 54-96-6; Amifampridine; 3,4-Pyridinediamine; 3,4-DAP; 4,5-Diaminopyridine; Pyridine, 3,4-diamino-; SC10; 3,4 Diaminopyridine; amifampridina; DTXSID6046715; RU4S6E2G0J; NSC-521760; DTXCID4026715; 5-22-11-00266 (Beilstein Handbook Reference)

GHS hazard classification

Reported hazard statements	H300 (94.2%), H311 (86.5%), H315 (86.5%), H319 (98.1%), H330 (94.2%), H335 (82.7%)

H300 (94.2%): Fatal if swallowed [Danger Acute toxicity, oral]

H311 (86.5%): Toxic in contact with skin [Danger Acute toxicity, dermal]

What the public record says

3,4-Diaminopyridine · CAS 54-96-6 · C5H7N3. UNII RU4S6E2G0J. Melting Point: 229; LogP: -0.5.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.